⌕
Tarsus Pharmaceuticals · TARS · Nasdaq
Tenet 34 · Weak
Compare
$78.20−0.61%At closeTenet 34 · Weak
$78.20−0.48 (−0.61%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Tarsus Pharmaceuticals (TARS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is TARS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 16, 2026 · 03:51 ET
8,971 Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC reduced its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 11.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commi…

TARS −0.6% todayRead at source ↗
● GlobeNewsWireNov 5, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:…

TARS −0.6% todayRead at source ↗
● MarketBeatNov 3, 2026 · 22:15 ET
Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a…

TARS −0.6% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 21:25 ET
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript…

TARS −0.6% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 20:55 ET
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.…

TARS −0.6% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Tarsus Reports Third Quarter 2026 Financial Results

Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product …

TARS −0.6% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 10:55 ET
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%

The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive tr…

TARS −0.6% todayRead at source ↗
● Seeking AlphaNov 1, 2026 · 07:29 ET
My 'Eye' Is On Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both low-risk and high-reward l…

TARS −0.6% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its th…

TARS −0.6% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served…

TARS −0.6% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 11:06 ET
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

TARS −0.6% todayRead at source ↗
● Seeking AlphaOct 6, 2026 · 08:55 ET
Tarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like Options

Tarsus Pharmaceuticals is transitioning from a single-product launch story to a cash-generating eye care platform, with XDEMVY now funding the business. TARS raised XDEMVY 2026 net sales guidance to $685–$705 million, wi…

TARS −0.6% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (AAOpt) 2026 Annual M…

TARS −0.6% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:16 ET
Citius Pharmaceuticals (NASDAQ:CTXR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Financial Analysis

Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tarsus Pharmaceuticals (NASDAQ: TARS - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based …

TARS −0.6% todayRead at source ↗
● GlobeNewsWireSep 4, 2026 · 08:38 ETCOMPANY'S OWN WORDS
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved therapy Strengthe…

TARS −0.6% todayRead at source ↗
● Defense WorldSep 4, 2026 · 03:27 ET
114,458 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission…

TARS −0.6% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthc…

TARS −0.6% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA34−0.4%
DLB4−3.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just TARS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.